Itera | $12,000,000 | (May 28, 2026)
ClearNote Health | $52,000,000 | (May 28, 2026)
Protuoso Biosciences | $9,500,000 | (May 28, 2026)
NextPoint Therapeutics, Inc.
- 15/02/2024
- Series B
- $42,500,000
Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis discovered by our scientist founders. Our goal is to deliver new options to people with cancer.
- Industry Biotechnology
- Website https://nextpointtx.com/
- LinkedIn https://www.linkedin.com/company/nextpoint-therapeutics/
Related People
Ivan CheungFounder
United States -
Scarsdale, New York
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 checkpoint axis. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond.
Fields Good | $1,800,000 | (May 28, 2026)
Cypher AI | $2,000,000 | (May 28, 2026)
C2i Semiconductors | $16,700,000 | (May 28, 2026)
Orbital Industries | $50,000,000 | (May 28, 2026)
Secretome Therapeutics | $30,000,000 | (May 28, 2026)
Pace(US) | $46,000,000 | (May 28, 2026)
Certo | $4,000,000 | (May 28, 2026)
Mykor | $5,360,920 | (May 28, 2026)
Go Swag | $5,000,000 | (May 27, 2026)